TAS2R9 is a gustducin-coupled bitter taste receptor expressed in gustatory tissues and extraorally in skin, gastrointestinal tract, and immune cells 123. The receptor signals through phospholipase C and the calcium-regulated cation channel TRPM5 to detect bitter compounds [UniProt]. TAS2R9 genetic variants influence bitter taste perception phenotypes; common polymorphisms in TAS2R9 predict individual differences in perceived bitterness of acesulfame potassium, explaining 13.4% of variance when combined with TAS2R31 variants 4. Functionally compromised TAS2R9 variants alter responses to ligands ofloxacin, procainamide, and pirenzapine, and are associated with altered glucose and insulin homeostasis, suggesting a link between gustatory chemosensation and metabolic disease 5. In extraoral tissues, TAS2R9 expression in human skin shows personalized patterns varying by sex and age 1, while in lung macrophages, TAS2R9 agonists (ofloxacin) suppress lipopolysaccharide-induced pro-inflammatory cytokine release 3. The CC genotype at rs3741845 in TAS2R9 is associated with gestational diabetes mellitus risk 6, indicating broader metabolic relevance beyond taste perception.